Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV EPS (Diluted)

EPS (Diluted) at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
-$0.46-235%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$0.07+70.8%
Alkermes logo
AlkermesALKS
$0.00-100%
TRV
Trevi Therapeutics, Inc.TRVI
-$0.090.0%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$3.49-1,486%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.5%
Enterprise value$4.9B+88.6%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemThree Months Ended March 31, 20262025
Income tax expense2611
Net income$89$47
Earnings per share
Basic$0.71$0.38
Diluted$0.69$0.38
Shares used in computing earnings per share
Basic124124
Diluted129125

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s EPS (diluted)?
Indivior Pharmaceuticals, Inc. (INDV) reported EPS (diluted) of $0.69 in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
Indivior Pharmaceuticals, Inc.'s EPS (diluted) increased by 81.6% year-over-year, from $0.38 to $0.69.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s EPS (diluted)?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s EPS (diluted) has grown at a 76.2% compound annual growth rate (CAGR), from -$0.30 to $1.64.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Indivior Pharmaceuticals, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude